Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 484

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1A
Chunk 484
---
 Units of Stock That Have Not Vested ($)  
    Equity
    Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested
 (#)  
    Equity
    Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not vested 
(#) 
  
    Erez Aminov 
     980,085  
     980,085  
         -  
    $5.02  
    8/27/34 
        -  
     -  
           -  
       - 

    Michelle Yanez 
     -  
     200,000  
     -  
    $5.02  
    8/27/34 
     -  
     -  
     -  
     - 
  
    Christopher Chapman 
     -  
     -  
     -  
     -  
      
     -  
     -  
     -  
     - 
  
    Nathen Fuentes 
     -  
     -  
     -  
     -  
      
     -  
     -  
     -  
     - 

Option
Exercises and Stock Vested

No
stock options were exercised by our executive officers during the year ended December 31, 2024.

2023
Omnibus Incentive Plan

Our
board of directors has adopted, and our stockholders have approved, the Telomir Pharmaceuticals, Inc. 2023 Omnibus Incentive Plan (the
“2023 Omnibus Plan”) which became effective upon the completion of our initial public offering on February 9, 2024. The 2023
Omnibus Plan will authorize the grant of incentive stock options, within the meaning of Section 422 of the Internal Revenue Code, to
our employees and any of our parent and subsidiary corporations’ employees, and the grant of non-statutory stock options, restricted
stock, restricted stock units, stock appreciation rights, performance units and performance shares to our employees, directors, and consultants
and any of our future subsidiary corporations’ employees and consultants. The following is a summary of certain terms and conditions
of the 2023 Omnibus Plan. This